Resultats globals: 8 registres trobats en 0.02 segons.
Articles, 8 registres trobats
Articles 8 registres trobats  
1.
10 p, 324.1 KB Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial / Jukema, J.Wouter (Leiden University Medical Center) ; Szarek, Michael (State University of New York) ; Zijlstra, Laurien E. (Leiden University Medical Center) ; de Silva, H.Asita (University of Kelaniya) ; Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ; Bittner, Vera A. (University of Alabama at Birmingham) ; Diaz, Rafael (Cardiovascular Institute of Rosario) ; Edelberg, Jay M. (Sanofi) ; Goodman, Shaun G. (St. Michael's Hospital. University of Toronto) ; Hanotin, Corinne (Sanofi) ; Harrington, Robert A. (Stanford University) ; Karpov, Yuri (Russian Cardiological Scientific-Productive Complex) ; Moryusef, Angèle (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals. Inc.) ; Prieto, Juan C. (University of Chile Clinical Hospital) ; Roe, Matthew T. (Duke University School of Medicine) ; White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ; Zeiher, Andreas Michael (Goethe University) ; Schwartz, Gregory G. (University of Colorado School of Medicine) ; Steg, P.Gabriel (Royal Brompton Hospital (Londres)) ; Cequier, Ángel (Hospital Universitari de Bellvitge) ; García-Dorado, David (Hospital Universitari Vall d'Hebron) ; Mata Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. [...]
2019 - 10.1016/j.jacc.2019.03.013
Journal of the American College of Cardiology, Vol. 74 Núm. 9 (march 2019) , p. 1167-1176  
2.
10 p, 536.2 KB Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease / Parker, W.A.E. (University of Sheffield) ; Gorog, D.A. (University of Hertfordshire) ; Geisler, T. (University of Tübingen) ; Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau) ; Sibbing, D. (Medizinische Klinik und Poliklinik I. Campus Großhadern) ; Rocca, B. (Catholic University) ; Storey, R.F. (University of Sheffield) ; Universitat Autònoma de Barcelona
Stroke is a common and devastating condition caused by atherothrombosis, thromboembolism, or haemorrhage. Patients with chronic coronary syndromes (CCS) or peripheral artery disease (PAD) are at increased risk of stroke because of shared pathophysiological mechanisms and risk-factor profiles. [...]
2021 - 10.1093/EURHEARTJ/SUAA165
European heart journal supplements, Vol. 22 (2021) , p. M26-M34  
3.
14 p, 423.1 KB Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice : The APALUSA Study / Vivencio, B. (Hospital Universitario Ramón y Cajal (Madrid)) ; Carlos, E. (Hospital Universitario La Paz (Madrid)) ; Carmen, S. (Hospital Universitario de la Princesa (Madrid)) ; Garcia-Moll, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Francisco, L. (Vascular Surgery Department. University Hospital Clínico)
This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were included. [...]
2022 - 10.3390/jcm11123554
Journal of clinical medicine, Vol. 11 Núm. 12 (June 2022) , p. 3554  
4.
25 p, 1.2 MB Antithrombotic therapy in diabetes : which, when, and for how long? / Ajjan, Ramzi A. (The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds) ; Kietsiriroje, Noppadol (Prince of Songkla University) ; Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau) ; Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau) ; Gorog, Diana A. (National Heart and Lung Institute, Dovehouse St) ; Angiolillo, Dominick J. (University of Florida) ; Russell, David A. (Leeds Vascular Institute) ; Rocca, Bianca (Catholic University School of Medicine, Rome) ; Storey, Robert F. (University of Sheffield) ; Universitat Autònoma de Barcelona
Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high vascular risk in individuals with DM. [...]
2021 - 10.1093/eurheartj/ehab128
European heart journal, Vol. 42 (march 2021) , p. 2235-2259  
5.
2 p, 162.5 KB Comments from the Editor of the Special Issue "Clinical Research on Diabetic Complications" / Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
With this Editorial, we are hereby presenting to the reader the Special Issue on "Clinical Research on Diabetic Complications". Chronic complications of diabetes mellitus have a major impact on the life of subjects with the disease, resulting in decreased quality of life and increased morbidity and mortality. [...]
2019 - 10.3390/jcm8122193
Journal of clinical medicine, Vol. 8 (december 2019)  
6.
15 p, 418.2 KB Reducing residual thrombotic risk in patients with peripheral artery disease : impact of the COMPASS trial / Hernández, José Luis (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ; Lozano-Sánchez, Francisco Santiago (Hospital Clínico Universitario (Salamanca)) ; Riambau, Vincent (Hospital Clínic i Provincial de Barcelona) ; Almendro-Delia, Manuel (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Cosín-Sales, Juan (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Bellmunt Montoya, Sergi (Hospital Universitari Vall d'Hebron) ; Garcia-Alegria, Javier (Hospital Costa del Sol (Marbella)) ; Garcia-Moll, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Gomez-Doblas, Juan José (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; González-Juanatey, José R (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ; Suarez Fernández, Carmen (Instituto de Investigación Hospital Universitario de la Princesa) ; Universitat Autònoma de Barcelona
Patients with peripheral artery disease (PAD) are at a high risk not only for the classical cardiovascular (CV) outcomes (major adverse cardiovascular events; MACE) but also for vascular limb events (major adverse limb events; MALE). [...]
2020 - 10.7573/dic.2020-5-5
Drugs in Context, Vol. 9 (july 2020)  
7.
9 p, 319.4 KB Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany / Castellsague, Jordi (RTI Health Solutions) ; Poblador-Plou, Beatriz (University of Zaragoza) ; Giner-Soriano, Maria (Universitat Autònoma de Barcelona) ; Linder, Marie (Karolinska Institutet (Estocolm, Suècia). Department of Medicine) ; Scholle, Oliver (Leibniz Institute for Prevention Research and Epidemiology. Department of Clinical Epidemiology) ; Calingaert, Brian (RTI Health Solutions) ; Bui, Christine (RTI Health Solutions) ; Arana, Alejandro (RTI Health Solutions) ; Laguna, Clara (University of Zaragoza) ; Gonzalez Rubio, Francisca (University of Zaragoza) ; Roso-Llorach, Albert (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Prados-Torres, Alexandra (University of Zaragoza) ; Perez-Gutthann, S. (RTI Health Solutions)
The purpose of the study is to evaluate the effectiveness of risk minimization measures-labeling changes and communication to health care professionals-recommended by the European Medicines Agency for use of cilostazol for the treatment of intermittent claudication in Europe. [...]
2018 - 10.1002/pds.4584
Pharmacoepidemiology and Drug Safety, Vol. 27 (july 2018) , p. 953-961  
8.
7 p, 365.1 KB Safety of cilostazol in peripheral artery disease : a cohort from a primary healthcare electronic database / Real, Jordi (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Serna, M. Catalina (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Giner-Soriano, Maria (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Forés Raurell, Rosa (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Pera, Guillem (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Ribes, Esther (Servei d'Atenció Primària Barcelonès Nord i Maresme. Direcció d'Atenció Primària de Lleida) ; Alzamora, M. Teresa (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Marsal, Josep Ramon (Hospital Universitari Vall d'Hebron) ; Heras, Antonio (Institut Català de la Salut. Centre d'Atenció Primària Riu Nord-Riu Sud Santa Coloma de Gramenet) ; Morros, Rosa (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Universitat Autònoma de Barcelona
Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. [...]
2018 - 10.1186/s12872-018-0822-4
BMC Cardiovascular disorders, Vol. 18 (may 2018)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.